Skip to main content
. 2023 Sep 27;16:2677–2686. doi: 10.2147/CCID.S427956

Figure 5.

Figure 5

Tolerability parameters assessed by clinical grading and participant self-reporting at baseline and Weeks 2, 4, 8, and 12. Investigator-assessed clinical grading and participant self-reported tolerability was assessed on a 4-point scale (0 = none, 1 = mild, 2 = moderate, 3 = severe). All assessments were compared to baseline. *p ≤ 0.031 vs baseline (signed-rank test).